Ocumetics Targets $4M for Clinical Trials and R&D
Company Announcements

Ocumetics Targets $4M for Clinical Trials and R&D

Ocumetics Technology Corp (TSE:OTC) has released an update.

Ocumetics Technology Corp. has announced a private placement of secured convertible debentures to raise up to $4 million. These funds are earmarked to support the company’s first in-human clinical trials and ongoing R&D, with an 18% annual interest rate and a two-year maturity. The debentures, convertible into common shares, will finance critical trials in the Dominican Republic, as per President and CEO Dean Burns.

For further insights into TSE:OTC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskOcumetics Unveils Breakthrough Adaptive Intraocular Lens
TipRanks Canadian Auto-Generated NewsdeskOcumetics Unveils New Injector System for Eye Surgery
TipRanks Canadian Auto-Generated NewsdeskOcumetics Kicks Off Landmark Vision Correction Study
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App